# A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061

> **NCT07241910** · PHASE1 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** SYH2061
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07241910
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2026-11-24
- **Final completion:** 2027-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241910, "A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07241910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*